Fortitude Family Office’s Biodesix BDSX Stock Holding History

Fortitude Family Office’s Portfolio BDSX Stock Details BDSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.48K	Hold	171	–	–	﹤0.01%	1212
2025 Q4	$1.16K	Hold	171	–	–	﹤0.01%	1398
2025 Q3	$1.29K	Buy	+171	New	+$1.31K	﹤0.01%	1442

Other funds holding BDSX

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Telemark Asset Management Boston, Massachusetts $1.08B AUM 70.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Fortitude Family Office's BDSX Position: Q1 2026 in Review

Fortitude Family Office held its Biodesix (BDSX) position steady in Q1 2026 at 171 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1212.

Fortitude Family Office first reported a position in BDSX in Q3 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold BDSX as of Q1 2026.

Fortitude Family Office held 171 shares of Biodesix worth $2.48K as of Q1 2026.
Fortitude Family Office left its Biodesix share count unchanged in Q1 2026.
Biodesix made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1212 holding.
Fortitude Family Office first reported a position in Biodesix in Q3 2025 and has held it in 3 quarters since.
40 funds tracked by Wall St. Rank held Biodesix as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.